Canaccord Genuity Maintains Buy on Hims & Hers Health, Raises Price Target to $40

Canaccord Genuity analyst Maria Ripps maintains Hims & Hers Health (NYSE: HIMS ) with a Buy and raises the price target from $32 to $40.